Anti-glaucoma preparations that do not contain benzalkonium chloride (BAK) were associated with a change in lubricant use in a study of 240 glaucoma patients, suggesting reduction in some ocular surface disease symptoms, according to research published online in 

Researchers in Australia conducted the OBSERVE clinical audit to track the impact of both BAK-free and BAK-containing intraocular pressure-lowering medications in patients with evidence of ocular surface disease. 

A prospective clinical audit was conducted from March 2012 to April 2013. It enrolled 375 patients, 64% of whom completed the audit. Upon enrolling, some of the patients were switched from BAK-containing to BAK-free anti-glaucoma products. Data was then collected on all patients via an online survey over a 16 to 30 week period. 

A significant reduction in the use of eye lubricants was reported in the patients who switched to BAK-free preparations. There was a significant improvement for patients in both groups in McMonnies Dry Eye Questionnaire score, and a significant decrease in both groups in the percentage of patients with low tear-film breakup time. Neither group demonstrated a significant change in IOP from pre-study levels.

To read the abstract of the study, click 

Articles

Glaucoma

Anti-glaucoma preparations that do not contain benzalkonium chloride (BAK) were associated with a change in lubricant use in a study of 240 glaucoma patients, suggesting reduction in some ocular surface disease symptoms, according to research published online.